Resected Melanoma
Resected melanoma refers to melanoma that has been surgically removed, often with the goal of preventing recurrence through adjuvant therapy.
Adjuvant Therapy Landscape
Standard of care for high-risk resected melanoma has evolved to include immune checkpoint inhibitors and targeted therapies. Recent developments include the integration of personalized mRNA vaccines.
Moderna Merck mRNA Vaccine + Keytruda
Significant progress has been made in combining personalized mRNA vaccines with existing immunotherapies for adjuvant treatment Moderna Merck mRNA Cancer Vaccine and Keytruda for Resected Melanoma Adjuvant Therapy.
- Trial Results: Moderna and Merck announced positive Phase 3 trial results for the personalized mRNA cancer vaccine Intismeran Autogene.
- Combination Therapy: The vaccine is evaluated in combination with Keytruda (pembrolizumab) for patients with resected melanoma.
- Significance: This represents a major development in personalized cancer treatment, aiming to reduce recurrence rates in high-risk populations.
Related Concepts
- Melanoma
- Immunotherapy
- Keytruda
- mRNA Vaccine
- Adjuvant Therapy